Dose‐escalated RT vs conventional dose RT: Time to death from any cause
Dose‐escalated RT showed no clear difference in time to death from any cause compared with conventional dose RT (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Dose‐escalated RT vs conventional dose RT Time to death from any cause · clinically localized and locally advanced prostate cancer Dose‐escalated RT showed no clear difference in time to death from any cause compared with conventional dose RT (moderate certainty). Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer (2023) · Cochrane Headline outcomes only | HR 0.98 [0.89, 1.09] | 9 studies · 5437 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.